ATE358176T1 - Menschliche dnase - Google Patents

Menschliche dnase

Info

Publication number
ATE358176T1
ATE358176T1 AT98105190T AT98105190T ATE358176T1 AT E358176 T1 ATE358176 T1 AT E358176T1 AT 98105190 T AT98105190 T AT 98105190T AT 98105190 T AT98105190 T AT 98105190T AT E358176 T1 ATE358176 T1 AT E358176T1
Authority
AT
Austria
Prior art keywords
human dnase
dna
human
therapeutic
obtaining
Prior art date
Application number
AT98105190T
Other languages
English (en)
Inventor
Steven Shak
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26965935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE358176(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE358176T1 publication Critical patent/ATE358176T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
AT98105190T 1988-12-23 1989-12-20 Menschliche dnase ATE358176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28995888A 1988-12-23 1988-12-23
US44803889A 1989-12-08 1989-12-08

Publications (1)

Publication Number Publication Date
ATE358176T1 true ATE358176T1 (de) 2007-04-15

Family

ID=26965935

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98105190T ATE358176T1 (de) 1988-12-23 1989-12-20 Menschliche dnase
AT90901443T ATE176924T1 (de) 1988-12-23 1989-12-20 Verfahren zur herstellung von menschlicher dnase

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT90901443T ATE176924T1 (de) 1988-12-23 1989-12-20 Verfahren zur herstellung von menschlicher dnase

Country Status (11)

Country Link
US (3) US20030044403A1 (de)
EP (2) EP0853121B1 (de)
JP (2) JP3162372B2 (de)
AT (2) ATE358176T1 (de)
AU (1) AU630658B2 (de)
BG (1) BG62870B2 (de)
CA (1) CA2006473C (de)
DE (2) DE68928934T2 (de)
ES (1) ES2130120T3 (de)
HU (1) HU211232A9 (de)
WO (1) WO1990007572A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3162372B2 (ja) * 1988-12-23 2001-04-25 ジェネンテク，インコーポレイテッド ヒトｄｎアーゼ
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
JP2986215B2 (ja) * 1994-03-04 1999-12-06 ジェネンテック インコーポレイテッド Ｄｎアーゼ含有医薬製剤
WO1995023854A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. IMPROVED DNase LIQUID SOLUTIONS
JPH09512715A (ja) * 1994-05-05 1997-12-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトｄｎａｓｅ
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
WO1996007735A1 (en) * 1994-09-06 1996-03-14 Seiichi Tanuma Novel deoxyribonuclease
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
MX9706429A (es) * 1995-02-24 1997-11-29 Genentech Inc Variantes de dnasa i humana.
WO1996026278A1 (en) * 1995-02-24 1996-08-29 Genentech, Inc. HUMAN DNase I VARIANTS
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
DE19521046C1 (de) * 1995-06-09 1996-08-08 Deutsches Krebsforsch Protein mit DNase-Aktivität
DE69736276T2 (de) * 1996-02-05 2007-08-30 Genentech Inc., San Francisco Menschliche dnase resistent gegen actininhibitoren
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6265195B1 (en) * 1996-04-25 2001-07-24 Genentech, Inc. Human DNase II
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
DE60035851D1 (de) * 1999-08-17 2007-09-20 Tanuma Deoxyribonuklease, dafür kodierendes gen und verfahren
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
EP2292273A3 (de) 2001-10-10 2011-11-23 BioGeneriX AG Remodellierung und Glycokonjugation von Peptiden
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
EP1433842B1 (de) * 2002-12-18 2011-01-05 Roche Diagnostics GmbH Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
US7118901B2 (en) 2002-12-18 2006-10-10 Roche Diagnostics Operations, Inc. Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
CA2520265C (en) 2003-04-09 2015-02-17 Bgp Products Operations Gmbh Aerosolization apparatus with capsule puncture alignment guide
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US8710012B2 (en) * 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
WO2006130034A1 (fr) * 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
DK2086642T3 (da) 2006-10-18 2014-09-29 Periness Ltd Dnase til behandling af subfertilitet hos mænd
EP2095825B8 (de) * 2006-11-28 2012-03-28 CLS Therapeutics Limited Verfahren zur behandlung von krankheiten des menschen im zusammenhang mit einem erhöhten desoxyribonucleinsäuregehalt in extrazellulären räumen von geweben und medizinische zubereitung zur durchführung des verfahrens
EP2144923B1 (de) 2007-04-03 2013-02-13 BioGeneriX AG Behandlungsverfahren mit glycopegyliertem g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
US9198957B2 (en) * 2011-01-31 2015-12-01 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
WO2014160284A1 (en) * 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of stroke
SI3063275T1 (sl) 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
JP6071018B2 (ja) * 2014-10-31 2017-02-01 Ｊｃｒファーマ株式会社 組換えヒトＤＮａｓｅＩの製造方法
NZ733912A (en) * 2015-01-04 2023-04-28 Protalix Ltd Modified dnase and uses thereof
WO2016118476A1 (en) 2015-01-20 2016-07-28 The Children's Medical Center Corporation Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
DE102015118011A1 (de) * 2015-10-22 2017-04-27 Human Med Ag Vorrichtung zur Transplantation von Körperfett
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
EP3351263A1 (de) * 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmazeutische zusammensetzung zur behandlung oder prävention von gewebeadhäsion
EP3740581A4 (de) 2018-01-16 2021-10-27 CLS Therapeutics Limited Behandlung von krankheiten durch leberexpression eines enzyms mit desoxyribonuklease (dnase)-aktivität
EP4225903A1 (de) 2020-10-07 2023-08-16 Protalix Ltd. Langwirkende dnase
US11993792B2 (en) 2021-05-27 2024-05-28 New England Biolabs, Inc. DNase I variants, compositions, methods, and kits

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Canada Packers Limited Isolation and purification of deoxyribonuclease
JPS55131389A (en) * 1979-04-02 1980-10-13 Amano Pharmaceut Co Ltd Purification of deoxyribonuclease i
JP3162372B2 (ja) * 1988-12-23 2001-04-25 ジェネンテク，インコーポレイテッド ヒトｄｎアーゼ
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
US6251648B1 (en) * 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase

Also Published As

Publication number Publication date
ES2130120T3 (es) 1999-07-01
BG62870B2 (bg) 2000-09-29
HU211232A9 (en) 1995-11-28
EP0449968A1 (de) 1991-10-09
CA2006473C (en) 2002-02-05
JP3162372B2 (ja) 2001-04-25
DE68929551T2 (de) 2008-03-06
DE68928934D1 (de) 1999-04-01
ATE176924T1 (de) 1999-03-15
EP0449968B1 (de) 1999-02-24
JPH04502406A (ja) 1992-05-07
AU630658B2 (en) 1992-11-05
US20030044403A1 (en) 2003-03-06
DE68929551D1 (de) 2007-05-10
EP0853121A3 (de) 1998-08-05
JP2001157580A (ja) 2001-06-12
DE68928934T2 (de) 1999-08-05
CA2006473A1 (en) 1990-06-23
US20080026426A1 (en) 2008-01-31
AU4826590A (en) 1990-08-01
EP0853121A2 (de) 1998-07-15
US7297526B2 (en) 2007-11-20
US20050009056A1 (en) 2005-01-13
WO1990007572A1 (en) 1990-07-12
EP0853121B1 (de) 2007-03-28

Similar Documents

Publication Publication Date Title
DE68929551D1 (de) Menschliche DNase
DE68906161D1 (de) Ballon fuer medizinische einrichtung und dessen herstellung.
EP0787802A3 (de)
NO883896D0 (no) Konjugater av cytokiner med immunglobuliner.
FI883936A7 (fi) Sokeritaudin hoito, hoidossa käyttökelpoiset valmisteet ja niiden valmistus
DK203187D0 (da) Human g-csf proteinekspression
DE68924162D1 (de) Stressproteine und verwendungen dafür.
FI874819L (fi) Human rekombinant endotelcell vaextfaktor.
DE3768694D1 (de) Kuenstliche haut und deren herstellung.
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
DK215287A (da) Dna-sekvenser, der koder for et protein med angiogen virkning, vektorer, vaertsceller og fremgangsmaader til udtrykkelse af proteinet, samt laegemidler indeholdende dette
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
FI883129A7 (fi) Menetelmä järjestäytyneiden, erityisesti ihmisestä peräisin olevien kollageenirakenteiden valmistamiseksi ja vastaavat järjestäytyneet kollageenirakenteet.
ATE148167T1 (de) Hybride plasminogenaktivatoren
FI913818A0 (fi) Nytt trombolytiskt aemne.
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
DE3785107D1 (de) Prepreg und dessen komposit.
IT8821743A0 (it) Materiali biologici, procedimenti per produrre materiali biologici e per usare tali materiali in terapia.
DE3579373D1 (de) Vinylchloridharzzusammensetzung und medizinisches instrument.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
ATE69549T1 (de) Erzeugnisse, enthaltend gallopamil und prazosin.
GR3005231T3 (de)
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
IT1230433B (it) Agente e procedimento per la concia del cuoio

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853121

Country of ref document: EP

EELA Cancelled due to lapse of time